echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: Attacks following hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinic (SLICC) initial cohort

    ARD: Attacks following hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinic (SLICC) initial cohort

    • Last Update: 2022-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com






    Source:

    Almeida-Brasil CC, Hanly JG, Urowitz M , et al .


    Almeida-Brasil CC, Hanly JG, Urowitz M , et al .
    Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Annals of the Rheumatic DiseasesPublished Online First: 15 December 2021.
    doi: 10.
    1136/annrheumdis-2021-221295 , et al Annals of the Rheumatic Diseases

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.